Back to Journals » Cancer Management and Research » Volume 11

Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date

Total article views   HTML views PDF downloads Totals
10,301 Dovepress* 6,371+ 1,394 7,765
PubMed Central* 3,930 798 4,728
Totals 10,301 2,192 12,493
*Since 29 May 2019
Total mentioned Facebook Delicious Reddit Twitter Others
5 0 0 1 1 3

View citations on PubMed Central and Google Scholar